CTRI/2018/03/012411已完成4 期
An open label, randomized, parallel group, comparative evaluation of safety and efficacy of Nadifloxacin 1% ointment versus Mupirocin 2% ointment in children with skin and soft tissue infection.
Dr Swapnil Janbandhu0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Male or female patients <12 years of age.
- •2.Patients suffering from mild to moderate bacterial SSTI including the following but not limited to impetigo, secondarily infected wounds, folliculitis, infected atopic dermatitis or furunculosis
- •3.Accompanying parent willing and able to understand study requirements and provide written informed consent form on behalf of the child if child is less than equal to 5 years. In case of child older than 5 years, willingness and ability of child to provide assent as well as to communicate with the investigator for study purpose.
排除标准
- •1.History of hypersensitivity to quinolones or mupirocin.
- •2.Receipt of any topical treatment at the same site within 1 week prior to study entry.
- •3.Receipt of any systemic antimicrobials within 1 week prior to study entry.
- •4.Receipt of any investigational drug within 4 weeks prior to study entry.
- •5.Patients with presence of any concomitant disease or health problem that may interfere in study assessments or endanger patient safety during study treatment.
- •6.Any other significant illness
研究者
相似试验
尚未招募
3 期
Comparative study between castor oil EMULGEL with clotrimazole vaginal tablet in the treatment of subjects with vulvo-vaginal candidiasis.CTRI/2023/04/051978D Y Patil University School of Medicine Navi Mumbai
尚未招募
3 期
se of HYDRODENG SACHET in Dengue fever patientsCTRI/2024/04/065599Tirupati Medicare Limited, India.
进行中（未招募）
不适用
Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain severe enough to require continuous opioid therapy - OROS hydromorphone once daily vs. Oxycodone twice daily in subjects with chronic non-malignant paiEUCTR2004-005187-24-DEJanssen Cilag Medical Affairs EMEA504
进行中（未招募）
不适用
Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain requiring continuous opioid therapyChronic non-malignant painEUCTR2004-005187-24-CZJanssen-Cilag Medical Affaires EMEA
进行中（未招募）
1 期
Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain requiring continuous opioid therapyEUCTR2004-005187-24-SKJanssen-Cilag Medical Affaires EMEA504